Par Drugs and Chemicals Limited has officially announced its audited standalone financial results for the quarter and year ended March 31, 2026, following a board meeting held on May 14, 2026. For the quarter ended March 31, 2026, the company reported revenue from operations of ₹1,961.08 Lakhs, representing a decline of 33.16% from the ₹2,933.95 Lakhs recorded in the previous quarter (QoQ) and a 12.18% decrease from the ₹2,232.99 Lakhs reported in the corresponding quarter of the previous year (YoY). The net profit for the quarter stood at ₹113.88 Lakhs, marking a significant drop of 76.28% compared to ₹480.05 Lakhs in the preceding quarter and a 31.06% decrease from ₹165.18 Lakhs in the same period last year.

Par Drugs and Chemicals Limited is a prominent Indian manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, with a particular focus on the antacid molecules segment. Established in 1999 and headquartered in Vadodara, Gujarat, the company produces a comprehensive range of products including Magnesium Hydroxide, Magnesium Trisilicate, and Dried Aluminium Hydroxide Gel for both domestic and international markets. As of late 2025, the company maintains a lean financial profile and is noted for being almost debt-free, operating from its G.I.D.C. industrial estate facility in Bhavnagar. Recent updates indicate that the promoter group, led by the Savani family, continues to hold a substantial 73.41% stake in the company as of March 2026. While the company is a consistent profit-maker, it has focused on reinvesting in its business operations rather than high dividend payouts.